Crinetics Pharmaceuticals, Inc.
General ticker "CRNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.3B (TTM average)
Crinetics Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 32.8%.
Estimated limits based on current volatility of 2.3%: low 45.52$, high 47.70$
Factors to consider:
- Total employees count: 437 (+50.7%) as of 2024
- Top business risk factors: Financing risks, Geopolitical risks, Labor/talent shortage/retention, Operational and conduct risks, Pandemic risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [31.06$, 66.97$]
- 2025-12-31 to 2026-12-31 estimated range: [20.99$, 47.72$]
Financial Metrics affecting the CRNX estimates:
- Negative: with PPE of -14.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.31 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -13.51
- Positive: Shareholder equity ratio, % of 92.35 > 63.39
Short-term CRNX quotes
Long-term CRNX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $4.74MM | $4.01MM | $1.04MM |
| Operating Expenses | $172.62MM | $226.62MM | $339.89MM |
| Operating Income | $-167.88MM | $-222.61MM | $-338.85MM |
| Non-Operating Income | $3.96MM | $8.08MM | $40.45MM |
| R&D Expense | $130.22MM | $168.53MM | $240.16MM |
| Income(Loss) | $-163.92MM | $-214.53MM | $-298.41MM |
| Profit(Loss)* | $-163.92MM | $-214.53MM | $-298.41MM |
| Stockholders Equity | $316.33MM | $539.11MM | $1,324.81MM |
| Assets | $352.18MM | $635.35MM | $1,434.59MM |
| Operating Cash Flow | $-115.20MM | $-166.31MM | $-225.97MM |
| Capital expenditure | $1.66MM | $4.69MM | $3.84MM |
| Investing Cash Flow | $-173.98MM | $-200.41MM | $-574.82MM |
| Financing Cash Flow | $121.96MM | $388.94MM | $1,010.43MM |
| Earnings Per Share** | $-3.15 | $-3.69 | $-3.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.